SAN DIEGO, CA — Sift Biosciences will be presenting at the 2026 BIO International Convention in San Diego. CEO and Co-Founder Dr. Yue Clare Lou will pitch Sift at Startup Stadium on Tuesday, June 23, 2026 from 11:55 AM – 12:05 PM in the Oncology track (room 5B).
“Closing our oversubscribed $3.7 million Pre-Seed round to advance our lead oncology asset and securing a partnership with a top-ten pharmaceutical company to develop our autoimmune program marked the start of an important year for Sift Biosciences,” said Dr. Lou. “We’re excited to be at BIO 2026 to meet the partners who can help us bring SIFT™ molecules to patients.”
Presentation Details
Event: 2026 BIO International Convention — Startup Stadium
Date: Tuesday, June 23, 2026
Time: 11:55 AM – 12:05 PM
Track: Oncology
Room: 5B
About Sift Biosciences
Sift Biosciences is a preclinical immunotherapy company developing immunomodulators that harness pre-existing memory T-cells to treat immune dysfunctions. Founded in 2024 as a UC Berkeley spin-out, Sift integrates AI and high-throughput T-cell screening to mine billions of microbial proteins for motifs that activate antimicrobial memory T-cells and steer them toward tumor antigens, autoantigens, and other disease-relevant targets. The company’s initial focus is on oncology, with expanding pipelines in autoimmunity and immunosenescence.